Actuate Therapeutics (ACTU) USPTO patents

Utility

Methods of Treating Malignant Lymphoproliferative Disorders

27 Apr 23

Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3β inhibitor, for example 9-ING-41, are provided.

Francis GILES, Andrew MAZAR

Filed: 3 Nov 22

Utility

Compounds for the Treatment of Myelofibrosis

2 Mar 23

The present invention provides methods of treating myelofibrosis in a patient by administering to the patient a therapeutically effective amount of a 08K-3β inhibitor such as 3-(5-fluorobenzofuran-3-y1)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-y1)pynOle-2,5-dione, or a pharmaceutically acceptable salt thereof, optionally in combination with a therapeutically effective amount of a JAK inhibitor such as ruxolitinib, or a pharmaceutically acceptable salt thereof.

Francis J. GILES, Andrew MAZAR

Filed: 23 Dec 20

Utility

x85epp1pxor 22thgiffyabg

29 Nov 22

Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3β inhibitor, for example 9-ING-41, are provided.

Francis Giles, Andrew Mazar

Filed: 5 Jun 19

Utility

ku1cu4xqwgsn0vkmc5tu9xoam8ksfby6v1

3 Nov 22

The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.

Yamin ZHANG

Filed: 1 Jul 22

Utility

kmulmwgabrl83wirye7fj8niegss s95fb

9 Aug 22

The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl) pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.

Yamin Zhang

Filed: 16 Oct 18

Utility

xwcooomnp 449h5c5s1mp1h3rwxf3jlgsf1jltyz1axp5fe3lkk

3 Feb 22

Methods of using immunohistochemical staining to identify cells expressing GSK-3 and use of such methods in treating disease are disclosed.

Andrey UGOLKOV

Filed: 12 Dec 19

Utility

9yl6ykvil4xrnnonbbpp44mydxrs6xzi2t7hsks46kyna ifwy

13 Jan 22

The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.

Yamin ZHANG

Filed: 24 Sep 21

Utility

jmqfzf0fo8okgynsv 05wp

5 Oct 21

The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.

Yamin Zhang

Filed: 10 Aug 18

Utility

m7ofrq4rbt834yki84rrqfiq48gc8ewcx

29 Jul 21

Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3β inhibitor, for example 9-ING41, are provided.

Francis GILES, Andrew MAZAR

Filed: 5 Jun 19

Utility

8dqciuoa8b0ul6w52k78wc5jh6tgr76rrux6rt4r7

15 Jul 21

Pharmaceutical compositions and methods are described which rely upon glycogen synthase kinase 3 (form β; GSK 3β) inhibitors, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo including proliferation and differentiation of myofibroblasts to fibrotic fibroblasts in several mouse models.

Torry A. TUCKER, Steven IDELL

Filed: 16 May 19

Utility

xrsj47wdyvy70inv9q5uvm6rs7rovi9x4aemrb0hyb 6mwndts5sx70

29 Jul 20

The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo [4,5-f]indol-7-yl) pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.

Yamin ZHANG

Filed: 15 Oct 18

Utility

ji6khzho3ueux1l5bnedx12h95kkt410s9i7z8tjvupbocfbjpmd6vo8n

15 Jul 20

The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in treating disease.

Yamin ZHANG

Filed: 9 Aug 18